SENSE Study: Remote Symptom Monitoring for Patients With Chemotherapy-induced Peripheral Neuropathy - Trial NCT05330104
Access comprehensive clinical trial information for NCT05330104 through Pure Global AI's free database. This phase not specified trial is sponsored by Allina Health System and is currently Recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Mobile Ecological Momentary Assessment
Interventional
behavioral
Sponsor & Location
Allina Health System
Timeline & Enrollment
N/A
Jan 03, 2022
Jan 03, 2024
Primary Outcome
Patient satisfaction with mEMA,Patient Adherence to mEMA
Summary
The main purpose of this study is to determine the threshold level of lower extremity CIPN
 symptoms that put patients who have been prescribed a neurotoxic chemotherapy agent (e.g.,
 paclitaxel, docetaxel, oxaliplatin or cisplatin) as part of their treatment regimen for
 cancer at-risk for falling. The investigators believe that by specifying early CIPN symptoms
 that predict fall-risk, The investigators will ultimately be able to identify at-risk
 patients who could be referred to rehabilitative services to prevent injurious falls while
 enabling them to continue the chemotherapy treatment that could save their lives.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05330104
Non-Device Trial